Scientific Evidence & Source Legend¶
This file documents the scientific and technical sources used to shape IINTS-AF defaults, validation targets, report framing, local AI setup guidance, and best-effort device emulation notes.
Scope: - Pre-clinical simulation and retrospective forecasting only. - Not a treatment recommendation engine. - Not a medical device.
Use iints sources to print the packaged source manifest from the installed SDK.
For the full public source index, including dataset registry sources and documentation-only implementation references, see Complete Source Library.
How To Read This Legend¶
There are two source buckets in this project:
-
Packaged evidence sources These are the core medical and dataset references shipped with the SDK and exposed through
iints sources. -
Documentation-only implementation sources These are the additional references used in the guides for:
- Ollama setup
- local open Mistral model selection
- best-effort device emulation context
That split is intentional: - the packaged manifest stays focused on repeatable research evidence - this page stays readable as the full legend for humans
Category Legend¶
| Category | Meaning |
|---|---|
guideline |
formal standards or standards-of-care style guidance |
consensus |
expert consensus used for interpretation targets |
trial |
clinical or comparative outcome study |
pharmacology |
insulin PK/PD reference |
sensor |
CGM behavior, lag, or sensor interpretation source |
model |
mathematical or simulator foundation source |
dataset |
public dataset provenance source |
runtime |
technical runtime or installation reference for local AI |
model_card |
model-family reference for local Mistral choices |
regulatory |
manufacturer or regulator-facing system reference |
technical_manual |
user guide or product documentation |
clinical_trial |
named trial registry or trial program page |
physiology |
human physiology or organ-system mechanism source |
review |
peer-reviewed review used to summarize established mechanisms |
How Sources Map to SDK Components¶
| SDK area | Why it exists | Source IDs |
|---|---|---|
Validation targets (TIR, TBR, TAR, hypoglycemia framing) |
Keep benchmark interpretation aligned with accepted diabetes metrics | ada_2026_glycemic_goals, attd_2019_time_in_range |
| CGM + AID context in docs/reports | Keep language aligned with current standards for technology use | ada_2026_diabetes_technology |
| AID benchmark envelopes | Compare algorithm behavior against realistic closed-loop outcomes | nejm_2019_control_iq, adapt_2022_ahcl |
| Meal timing / pre-bolus scenarios | Avoid unrealistic meal-response assumptions | cobry_2010_meal_bolus_timing |
| Insulin action profiles (rapid and ultra-rapid) | Parameterize onset/peak assumptions from pharmacology literature | heise_2017_fiasp_pkpd, klaff_2020_urli_pkpd |
| Input validation and CGM lag rationale | Keep signal handling biologically plausible | wentholt_2004_cgm_lag |
| Sensor long-memory noise model | Add colored, persistent CGM noise without claiming exact vendor reproduction | mandelbrot_1968_fractional_brownian |
| Virtual patient meal dynamics | Ground meal disturbance dynamics in established models | dalla_man_2007_meal_model |
| Bergman/Hovorka patient model foundations | Ground internal glucose, insulin, and insulin-action state variables in established mathematical physiology | bergman_1979_minimal_model, hovorka_2004_nmpc_t1d, dalla_man_2007_meal_model |
| Circadian, exercise, and incretin physiology | Document experimental dawn, GLUT4/NIMGU, and GLP-1 gastric-emptying modifiers | campbell_1985_dawn_phenomenon, richter_2013_glut4_exercise, naslund_1999_glp1_gastric_emptying |
| Hypoglycemia counterregulation and HAAF experimental layer | Make the body's rescue mechanisms, repeated-low memory, and hypo-awareness assumptions explicit | gerich_1979_counterregulation, cryer_2013_haaf_mechanisms, cryer_2013_haaf_diabetes |
| Bi-hormonal glucagon research | Separate delivered glucagon, subcutaneous absorption, plasma appearance, and closed-loop dual-hormone context | lv_2013_exogenous_glucagon_pk, haidar_2013_insulin_glucagon_pk, haidar_2013_dual_hormone_ap |
| Renal glucose clearance experimental layer | Document high-glucose renal threshold/splay behavior for whole-day mass-balance realism | hummel_2018_renal_glucose_handling, defronzo_2013_renal_reabsorption_splay |
| Simulator realism/validation framing | Align in-silico model evaluation with accepted simulator literature | visentin_2018_uvapadova, mujahid_2024_generative_t1d_simulator |
| Exercise stress scenarios | Use consensus guidance for exercise-related glucose behavior | riddell_2017_exercise_consensus |
| Forecast training data provenance | Use publicly documented dataset references | marling_2020_ohiot1dm |
| AGP-style research reports | Present dense glucose traces with time-in-ranges, modal-day percentile bands, and daily profiles | idc_2025_agp_report_overview, attd_2019_time_in_range |
| Local AI setup and model selection docs | Keep Ollama and open Mistral setup instructions grounded in official docs | ollama_linux_install, mistral_2025_ministral_3_announcement, mistral_2025_ministral_3_3b, mistral_2025_ministral_3_8b, mistral_2025_ministral_3_14b |
| Device emulation notes | Provide best-effort references behind 780G / Control-IQ / Omnipod 5 approximations | bergenstal_2020_780g, fda_k193510_780g, medtronic_780g_user_guide, brown_2019_control_iq_dtt, fda_k191289_control_iq, idcl_nct03563313, control_iq_user_guide, assert_omnipod_5, onset_omnipod_5, fda_k203467_omnipod5, omnipod5_user_guide |
Packaged Medical And Dataset Sources¶
-
ada_2026_glycemic_goalsADA Professional Practice Committee. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2026. DOI: 10.2337/dc26-S006 -
ada_2026_diabetes_technologyADA Professional Practice Committee. Diabetes Technology: Standards of Care in Diabetes—2026. DOI: 10.2337/dc26-S007 -
attd_2019_time_in_rangeBattelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation. Diabetes Care. 2019. DOI: 10.2337/dci19-0028 -
nejm_2019_control_iqBrown SA, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med. 2019. DOI: 10.1056/NEJMoa1907863 -
adapt_2022_ahclBenhamou PY, et al. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT). Lancet Diabetes Endocrinol. 2022. DOI: 10.1016/S2213-8587(22)00212-1 -
cobry_2010_meal_bolus_timingCobry E, et al. Timing of Meal Insulin Boluses to Achieve Optimal Postprandial Glycemic Control. J Diabetes Sci Technol. 2010. DOI: 10.1177/193229681000400404 -
heise_2017_fiasp_pkpdHeise T, et al. A Faster-Onset Formulation of Insulin Aspart. Clin Pharmacokinet. 2017. DOI: 10.1007/s40262-017-0510-8 -
klaff_2020_urli_pkpdKlaff LJ, et al. Ultra Rapid Lispro Demonstrates Accelerated Pharmacokinetics and Pharmacodynamics. Diabetes Obes Metab. 2020. DOI: 10.1111/dom.14049 -
wentholt_2004_cgm_lagWentholt IME, et al. How glucose sensors can facilitate therapy in diabetes management. Diabetes Technol Ther. 2004. DOI: 10.1089/dia.2004.6.615 -
dalla_man_2007_meal_modelDalla Man C, Rizza RA, Cobelli C. Meal simulation model of the glucose-insulin system. IEEE Trans Biomed Eng. 2007. DOI: 10.1109/TBME.2007.893506 -
visentin_2018_uvapadovaVisentin R, et al. The University of Virginia/Padova Type 1 Diabetes Simulator Matches the 2014 DMMS.R. J Diabetes Sci Technol. 2018. DOI: 10.1177/1932296818757747 -
mujahid_2024_generative_t1d_simulatorMujahid O, Contreras I, Beneyto A, Vehi J. Generative deep learning for the development of a type 1 diabetes simulator. Communications Medicine. 2024. DOI: 10.1038/s43856-024-00476-0 -
riddell_2017_exercise_consensusRiddell MC, et al. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol. 2017. DOI: 10.1016/S2213-8587(17)30014-1 -
marling_2020_ohiot1dmMarling C, Bunescu R. The OhioT1DM Dataset for Blood Glucose Level Prediction: Update 2020. CEUR Workshop Proceedings. Paper: ceur-ws.org/Vol-2675/paper2.pdf -
idc_2025_agp_report_overviewHealthPartners Institute / International Diabetes Center. Guide to Understanding the Ambulatory Glucose Profile (AGP) Report. 2025. PDF: healthpartners.com -
bergman_1979_minimal_modelBergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol. 1979. DOI: 10.1152/ajpendo.1979.236.6.E667 -
hovorka_2004_nmpc_t1dHovorka R, et al. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas. 2004. DOI: 10.1088/0967-3334/25/4/010 -
gerich_1979_counterregulationGerich J, Davis J, Lorenzi M. Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man. Am J Physiol. 1979. DOI: 10.1152/ajpendo.1979.236.4.E380 -
cryer_2013_haaf_mechanismsCryer PE. Mechanisms of Hypoglycemia-Associated Autonomic Failure in Diabetes. N Engl J Med. 2013. DOI: 10.1056/NEJMra1215228 -
cryer_2013_haaf_diabetesCryer PE. Hypoglycemia-associated autonomic failure in diabetes. Handb Clin Neurol. 2013. DOI: 10.1016/B978-0-444-53491-0.00023-7 -
lv_2013_exogenous_glucagon_pkLv D, Breton MD, Farhy LS. Pharmacokinetics modeling of exogenous glucagon in type 1 diabetes mellitus patients. Diabetes Technol Ther. 2013. DOI: 10.1089/dia.2013.0150 -
haidar_2013_dual_hormone_apHaidar A, et al. Glucose-responsive insulin and glucagon delivery in adults with type 1 diabetes. CMAJ. 2013. DOI: 10.1503/cmaj.121265 -
haidar_2013_insulin_glucagon_pkHaidar A, Duval C, Legault L, Rabasa-Lhoret R. Pharmacokinetics of Insulin Aspart and Glucagon in Type 1 Diabetes during Closed-Loop Operation. J Diabetes Sci Technol. 2013. DOI: 10.1177/193229681300700610 -
hummel_2018_renal_glucose_handlingHummel CS, Lu C, Loo DDF, Hirayama BA, Voss AA, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. 2018. DOI: 10.1007/s00125-018-4656-5 -
defronzo_2013_renal_reabsorption_splayDeFronzo RA, et al. Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin. Diabetes Care. 2013. DOI: 10.2337/dc13-0387 -
mandelbrot_1968_fractional_brownianMandelbrot BB, Van Ness JW. Fractional Brownian Motions, Fractional Noises and Applications. SIAM Review. 1968. DOI: 10.1137/1010093 -
campbell_1985_dawn_phenomenonCampbell PJ, Bolli GB, Cryer PE, Gerich JE. Pathogenesis of the Dawn Phenomenon in Patients with Insulin-Dependent Diabetes Mellitus. N Engl J Med. 1985. DOI: 10.1056/NEJM198506063122302 -
richter_2013_glut4_exerciseRichter EA, Hargreaves M. Exercise, GLUT4, and skeletal muscle glucose uptake. Physiol Rev. 2013. DOI: 10.1152/physrev.00038.2012 -
naslund_1999_glp1_gastric_emptyingNaslund E, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol Regul Integr Comp Physiol. 1999. DOI: 10.1152/ajpregu.1999.277.3.R910
Documentation-Only Local AI Setup Sources¶
These are the official references used in the guides for installing Ollama, understanding the local Ministral 3 family, and explaining why the SDK recommends different model sizes for different hardware.
-
ollama_linux_installOllama. Linux Installation Documentation. URL: docs.ollama.com/linux -
mistral_2025_ministral_3_announcementMistral AI. Introducing Mistral 3. URL: mistral.ai/news/mistral-3 -
mistral_2025_ministral_3_3bMistral AI Docs. Ministral 3 3B. URL: docs.mistral.ai/models/ministral-3-3b-25-12 -
mistral_2025_ministral_3_8bMistral AI Docs. Ministral 3 8B. URL: docs.mistral.ai/models/ministral-3-8b-25-12 -
mistral_2025_ministral_3_14bMistral AI Docs. Ministral 3 14B. URL: docs.mistral.ai/models/ministral-3-14b-25-12 -
mistral_2026_adjustable_reasoningMistral AI Docs. Adjustable Reasoning. URL: docs.mistral.ai/studio-api/conversations/reasoning/adjustable -
mistral_2026_small_4Mistral AI Docs. Mistral Small 4. URL: docs.mistral.ai/models/model-cards/mistral-small-4-0-26-03 -
mistral_2026_medium_35Mistral AI Docs. Mistral Medium 3.5. URL: docs.mistral.ai/models/model-cards/mistral-medium-3-5-26-04
Documentation-Only Device Emulation References¶
These references are used for the best-effort emulator notes and are not claims of exact proprietary algorithm reproduction.
Medtronic MiniMed 780G¶
-
bergenstal_2020_780gBergenstal RM, et al. Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. DOI: 10.1056/NEJMoa2003479 -
fda_k193510_780gU.S. FDA. 510(k) K193510 - MiniMed 780G System. URL: accessdata.fda.gov -
medtronic_780g_user_guideMedtronic Diabetes. MiniMed 780G User Guide / Product Documentation. URL: medtronicdiabetes.com
Tandem Control-IQ¶
-
brown_2019_control_iq_dttBrown SA, et al. Performance of the Tandem t:slim X2 insulin pump with Control-IQ technology in the International Diabetes Closed-Loop trial. DOI: 10.1089/dia.2019.0226 -
fda_k191289_control_iqU.S. FDA. 510(k) K191289 - Control-IQ System. URL: accessdata.fda.gov -
idcl_nct03563313ClinicalTrials.gov. International Diabetes Closed Loop Trial. URL: clinicaltrials.gov/ct2/show/NCT03563313 -
control_iq_user_guideTandem Diabetes Care. Control-IQ User Guide / Product Documentation. URL: tandemdiabetes.com
Omnipod 5¶
-
assert_omnipod_5Insulet / Omnipod. ASSERT Trial - Omnipod 5. URL: omnipod.com/assert-trial -
onset_omnipod_5Insulet / Omnipod. ONSET Trial - Omnipod 5 in Type 2 Diabetes. URL: omnipod.com/onset-trial -
fda_k203467_omnipod5U.S. FDA. 510(k) K203467 - Omnipod 5 System. URL: accessdata.fda.gov -
omnipod5_user_guideInsulet / Omnipod. Omnipod 5 User Guide / Product Documentation. URL: omnipod.com
Reproducibility Note¶
For report reproducibility, pair this file with:
- run metadata (run_metadata.json)
- manifest hashes (run_manifest.json)
- dataset lineage fields in research outputs (source_file_sha256, split metadata).
If you want the machine-readable packaged subset, export it with:
iints sources --output-json results/source_manifest.json